Track NSI‑189 in Peptimes™
NSI-189 (amdiglurax) is a small molecule, not a peptide: (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone, with the formula C22H30N4O. (Source: FDA's substance registry (GSRS).)
Is NSI-189 FDA-approved?
No. NSI-189 is investigational: it has been studied in registered clinical trials and isn't FDA-approved for any use.
NSI-189
Also: amdiglurax, NSI-189 phosphate
- Status label in the Peptimes Library
- Phase 2 Trials
- Routes in Peptimes
- Oral
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-approved for any use. Drugs@FDA lists no application with NSI-189 (amdiglurax) as an active ingredient.
Source: Drugs@FDA, checked 1 Nov 2026
Investigational
Yes.
Source: ClinicalTrials.gov, checked 1 Nov 2026
How to track it in Peptimes
Add NSI-189 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 2 Trials”, which describes its investigational status. It isn’t an approval.
- Logging: the amount you took and how you feel. It’s logged as oral, so there’s no injection site to record.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell NSI-189 or any other compound.
More sources
- NIH, ClinicalTrials.gov, NCT02695472, checked 1 Nov 2026: a Phase 2 study of NSI-189 in major depressive disorder. ClinicalTrials.gov also lists other studies of NSI-189, including two completed Phase 1 studies.
- FDA, Drugs@FDA, checked 1 Nov 2026: no application lists NSI-189 or amdiglurax as an active ingredient.
- FDA, Global Substance Registration System, Amdiglurax, checked 1 Nov 2026: its chemical name and formula, and the names NSI-189 and amdiglurax.